Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

Purpose of the study is to determine whether multiple dose administration of PF-04360365 is safe and well tolerated in patient with mild to moderate Alzheimer's disease.

Key facts

Study ID

NCT00722046

Run by

Pfizer

People needed

198

Starts

2008-12-05

Expected to finish

2011-08-16

Last updated by the study team

2022-11-07

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females of non childbearing potential, age > or = 50
• Diagnosis of probable Alzheimer's disease, consistent with criterial from both:
• National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
• Diagnostic and Statistical Manual of Mental Disorders (DSM IV)
• Mini-mental status exam score of 16-26 inclusive
• Rosen-Modified Hachinski Ischemia Score of < or = 4

You may not qualify if…

• Diagnosis or history of other demential or neurodegenerative disorders
• Diagnosis or history of clinically significant cerebrovascular disease
• Specific findings on magnetic resonance imaging (MRI); cortical infarct, micro hemorrhage, multiple white matter lacunes, extensive white matter abnormalities
• History of autoimmune disorders
• History of allergic or anaphylactic reactions

Where it is running

• Pivotal Research Center — Peoria, Arizona, United States
• Sun Radiology- for MRI — Peoria, Arizona, United States
• Dedicated Phase 1 — Phoenix, Arizona, United States
• Neuroscience Consultants, LLC — Miami, Florida, United States
• Miami Research Associates — South Miami, Florida, United States
• MRA Clinical Research — South Miami, Florida, United States
• Sleep Florida, LLC — South Miami, Florida, United States
• Alexian Brothers Medical Center — Elk Grove Village, Illinois, United States
• Alexian Brothers Neurosciences Institute — Elk Grove Village, Illinois, United States
• Stark Pharmacy — Overland Park, Kansas, United States
• Vince and Associates Clinical Research — Overland Park, Kansas, United States
• Vince and Associates Clinical Research — Overland Park, Kansas, United States
• Memory Enhancement Center of America, Inc — Eatontown, New Jersey, United States
• Central Jersey Radiology — Oakhurst, New Jersey, United States
• Butler Hospital — Providence, Rhode Island, United States
• Royal Adelaide Hospital — Adelaide, South Australia, Australia
• The Queen Elizabeth Hospital and Health Service — Woodville South, South Australia, Australia
• Heidelberg Repatriation Hospital, Austin Health — Heidelberg West, Victoria, Australia
• The McCusker Foundation for Alzheimer's Disease Research — Nedlands, Western Australia, Australia
• ZNA Middelheim / Neurology — Antwerp, Belgium
• UZ Antwerpen, Department of Neurology — Edegem, Belgium
• UZ Brussel / Geriatrie — Jette, Belgium
• U.Z. Gasthuisberg / Neurologie — Leuven, Belgium
• University of British Columbia Hospital, Division of Neurology — Vancouver, British Columbia, Canada
• Parkwood Hospital, Geriatric Medicine — London, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.